Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(8):1072–1080. doi: 10.1038/bjc.1997.510

Induction of anti-tumour lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes.

C N Baxevanis 1, M L Tsiatas 1, N T Cacoullos 1, G Spanakos 1, C Liacos 1, I Missitzis 1, S I Papadhimitriou 1, M Papamichail 1
PMCID: PMC2228087  PMID: 9376269

Abstract

The present study investigated the ability of supernatants collected from cultures of healthy donor-derived peripheral blood mononuclear cells (HD-PBMCs) stimulated with anti-CD3 monoclonal antibody (MAb) (allogeneic CD3 supernatants; ACD3S) to induce, upon brief exposure, tumour-reactive cytotoxic lymphocytes in cancer patients' PBMCs. ACD3S enhanced natural killer (NK) and lymphokine-activated killer (LAK) cell-mediated cytotoxicity. ACD3S contained increased levels of interleukins (IL) 1, 2, 6, 7 and 12, as well as of granulocyte-macrophage colony-stimulating factor (GM-CSF), gamma-interferon (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha). MAbs against these cytokines significantly reduced the ACD3S-induced cytotoxicity. ACD3S-induced cytotoxicity was not inhibited by anti-CD4, CD8 and MHC class I MAbs, but was markedly reduced in the presence of MAb against CD18. In contrast to HD-PBMC, ACD3S derived from cancer patients' lymphocytes exhibited lower levels of the above-mentioned cytokines and exerted reduced biological activity. In conclusion, ACD3S are able to activate, upon short-term incubation, tumour-reactive lymphocytes from cancer patients' PBMCs that lyse a variety of tumour targets, including autologous tumours. ACD3S contain high levels of certain cytokines that positively influence the induction of autologous tumour-reactive lymphocytes. Such supernatants can be collected easily from healthy donors and stored until use in clinical trials for adoptive cellular therapy of cancer. They may also be indicated in the construction of cytokine cocktails that have the ability to induce anti-tumour cytotoxicity.

Full text

PDF
1072

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J. P., Kudoh S., Melsop K. A., Hamilton T. A., Edinger M. G., Tubbs R. R., Sica D., Tuason L., Klein E., Bukowski R. M. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993 Mar 15;53(6):1380–1387. [PubMed] [Google Scholar]
  2. Anastasopoulos E., Reclos G. J., Baxevanis C. N., Gritzapis A. D., Tsilivakos V., Panagiotopoulos N., Fotiou S., Missitzis I., Karydas I., Papamichail M. Monocyte disorders associated with T cell defects in patients with solid tumors. Anticancer Res. 1992 Mar-Apr;12(2):489–494. [PubMed] [Google Scholar]
  3. Aoki T., Kikuchi H., Miyatake S., Oda Y., Iwasaki K., Yamasaki T., Kinashi T., Honjo T. Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity. J Exp Med. 1989 Aug 1;170(2):583–588. doi: 10.1084/jem.170.2.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Armitage R. J., Namen A. E., Sassenfeld H. M., Grabstein K. H. Regulation of human T cell proliferation by IL-7. J Immunol. 1990 Feb 1;144(3):938–941. [PubMed] [Google Scholar]
  5. Balch C. M., Tilden A. B., Dougherty P. A., Cloud G. A. Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg. 1983 Aug;198(2):192–199. doi: 10.1097/00000658-198308000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Baxevanis C. N., Dedoussis G. V., Papadopoulos N. G., Missitzis I., Beroukas C., Stathopoulos G. P., Papamichail M. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Cancer. 1995 Oct 1;76(7):1253–1260. doi: 10.1002/1097-0142(19951001)76:7<1253::aid-cncr2820760724>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  7. Baxevanis C. N., Dedoussis G. V., Papadopoulos N. G., Missitzis I., Stathopoulos G. P., Papamichail M. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer. 1994 Aug 15;74(4):1275–1282. doi: 10.1002/1097-0142(19940815)74:4<1275::aid-cncr2820740416>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  8. Baxevanis C. N., Papamichail M. Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy. Crit Rev Oncol Hematol. 1994 Jun;16(3):157–179. doi: 10.1016/1040-8428(94)90069-8. [DOI] [PubMed] [Google Scholar]
  9. Baxevanis C. N., Reclos G. J., Gritzapis A. D., Dedousis G. V., Arsenis P., Katsiyiannis A., Mitsis P. G., Tsavaris N., Papamichail M. Comparison of immune parameters in patients with one or two primary malignant neoplasms. Nat Immun. 1993 Jan-Feb;12(1):41–49. [PubMed] [Google Scholar]
  10. Baxevanis C. N., Reclos G. J., Gritzapis A. D., Dedousis G. V., Missitzis I., Papamichail M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer. 1993 Jul 15;72(2):491–501. doi: 10.1002/1097-0142(19930715)72:2<491::aid-cncr2820720227>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  11. Baxevanis C. N., Reclos G. J., Papamichail M. Prothymosin alpha restores depressed allogeneic cell-mediated lympholysis and natural-killer-cell activity in patients with cancer. Int J Cancer. 1993 Jan 21;53(2):264–268. doi: 10.1002/ijc.2910530216. [DOI] [PubMed] [Google Scholar]
  12. Blanchard D. K., Hall R. E., Djeu J. Y. Role of CD18 in lymphokine activated killer (LAK) cell-mediated lysis of human monocytes: comparison with other LAK targets. Int J Cancer. 1990 Feb 15;45(2):312–319. doi: 10.1002/ijc.2910450218. [DOI] [PubMed] [Google Scholar]
  13. Curti B. D., Longo D. L., Ochoa A. C., Conlon K. C., Smith J. W., 2nd, Alvord W. G., Creekmore S. P., Fenton R. G., Gause B. L., Holmlund J. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol. 1993 Apr;11(4):652–660. doi: 10.1200/JCO.1993.11.4.652. [DOI] [PubMed] [Google Scholar]
  14. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539–3543. doi: 10.1073/pnas.90.8.3539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ettinghausen S. E., Rosenberg S. A. Immunotherapy and gene therapy of cancer. Adv Surg. 1995;28:223–254. [PubMed] [Google Scholar]
  16. Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991 Dec 1;147(11):3815–3822. [PubMed] [Google Scholar]
  17. Fujiwara T., Grimm E. A. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction. J Immunol. 1992 May 1;148(9):2941–2946. [PubMed] [Google Scholar]
  18. Gamero A. M., Ussery D., Reintgen D. S., Puleo C. A., Djeu J. Y. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res. 1995 Nov 1;55(21):4988–4994. [PubMed] [Google Scholar]
  19. Gately M. K., Gubler U., Brunda M. J., Nadeau R. R., Anderson T. D., Lipman J. M., Sarmiento U. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol. 1994 Jun;1(3):187–196. [PubMed] [Google Scholar]
  20. Goedegebuure P. S., Douville L. M., Li H., Richmond G. C., Schoof D. D., Scavone M., Eberlein T. J. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol. 1995 Aug;13(8):1939–1949. doi: 10.1200/JCO.1995.13.8.1939. [DOI] [PubMed] [Google Scholar]
  21. Goedegebuure P. S., Zuber M., Leonard-Vidal D. L., Burger U. L., Cusack J. C., Jr, Chang M. P., Douville L. M., Eberlein T. J. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg Oncol. 1994 Apr;3(2):79–89. doi: 10.1016/0960-7404(94)90003-5. [DOI] [PubMed] [Google Scholar]
  22. Kaneko T., Fusauch Y., Kakui Y., Okumura K., Mizoguchi H., Oshimi K. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. Leuk Lymphoma. 1994 Jul;14(3-4):219–229. doi: 10.3109/10428199409049672. [DOI] [PubMed] [Google Scholar]
  23. Katsanis E., Xu Z., Anderson P. M., Dancisak B. B., Bausero M. A., Weisdorf D. J., Blazar B. R., Ochoa A. C. Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity. Bone Marrow Transplant. 1994 Oct;14(4):563–572. [PubMed] [Google Scholar]
  24. Kim J. A., Martin E. W., Jr, Morgan C. J., Aldrich W., Triozzi P. L. Expansion of mucin-reactive T-helper lymphocytes from patients with colorectal cancer. Cancer Biother. 1995 Summer;10(2):115–123. doi: 10.1089/cbr.1995.10.115. [DOI] [PubMed] [Google Scholar]
  25. Kosmidis P. A., Baxevanis C. N., Tsavaris N., Papanastasiou M., Anastasopoulos E., Bacoyiannis C., Mylonakis N., Karvounis N., Bafaloukos D., Karabelis A. The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b. J Clin Oncol. 1992 Jul;10(7):1153–1157. doi: 10.1200/JCO.1992.10.7.1153. [DOI] [PubMed] [Google Scholar]
  26. Mehrotra P. T., Grant A. J., Siegel J. P. Synergistic effects of IL-7 and IL-12 on human T cell activation. J Immunol. 1995 May 15;154(10):5093–5102. [PubMed] [Google Scholar]
  27. Miescher S., Stoeck M., Qiao L., Barras C., Barrelet L., von Fliedner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer. 1988 Nov 15;42(5):659–666. doi: 10.1002/ijc.2910420504. [DOI] [PubMed] [Google Scholar]
  28. Miescher S., Whiteside T. L., Moretta L., von Fliedner V. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol. 1987 Jun 1;138(11):4004–4011. [PubMed] [Google Scholar]
  29. Mulé J. J., Smith C. A., Rosenberg S. A. Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med. 1987 Sep 1;166(3):792–797. doi: 10.1084/jem.166.3.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nakajima F., Khanna A., Xu G., Lagman M., Haschemeyer R., Mouradian J., Wang J. C., Stenzel K. H., Rubin A. L., Suthanthiran M. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):7889–7893. doi: 10.1073/pnas.91.17.7889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Nastala C. L., Edington H. D., McKinney T. G., Tahara H., Nalesnik M. A., Brunda M. J., Gately M. K., Wolf S. F., Schreiber R. D., Storkus W. J. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994 Aug 15;153(4):1697–1706. [PubMed] [Google Scholar]
  32. Naume B., Espevik T. Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study. J Immunol. 1991 Oct 1;147(7):2208–2214. [PubMed] [Google Scholar]
  33. Osband M. E., Lavin P. T., Babayan R. K., Graham S., Lamm D. L., Parker B., Sawczuk I., Ross S., Krane R. J. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet. 1990 Apr 28;335(8696):994–998. doi: 10.1016/0140-6736(90)91064-h. [DOI] [PubMed] [Google Scholar]
  34. Owen-Schaub L. B., Gutterman J. U., Grimm E. A. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 1988 Feb 15;48(4):788–792. [PubMed] [Google Scholar]
  35. Papamichail M., Baxevanis C. N. Gamma-interferon enhances the cytotoxic activity of interleukin-2-induced peripheral blood lymphocyte (LAK) cells, tumor infiltrating lymphocytes (TIL), and effusion associated lymphocytes. J Chemother. 1992 Dec;4(6):387–393. doi: 10.1080/1120009x.1992.11739197. [DOI] [PubMed] [Google Scholar]
  36. Porgador A., Bannerji R., Watanabe Y., Feldman M., Gilboa E., Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. J Immunol. 1993 Feb 15;150(4):1458–1470. [PubMed] [Google Scholar]
  37. Sone S., Utsugi T., Nii A., Ogura T. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity. J Natl Cancer Inst. 1988 May 18;80(6):425–431. doi: 10.1093/jnci/80.6.425. [DOI] [PubMed] [Google Scholar]
  38. Suthanthiran M., Williams P. S., Solomon S. D., Rubin A. L., Stenzel K. H. Induction of cytolytic activity by anti-T3 monoclonal antibody. Activation of alloimmune memory cells and natural killer cells from normal and immunodeficient individuals. J Clin Invest. 1984 Dec;74(6):2263–2271. doi: 10.1172/JCI111653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Taga K., Mostowski H., Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood. 1993 Jun 1;81(11):2964–2971. [PubMed] [Google Scholar]
  40. Tani M., Tanimura H., Yamaue H., Mizobata S., Iwahashi M., Tsunoda T., Noguchi K., Tamai M., Hotta T., Terasawa H. Generation of CD4+ cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer. 1995 Mar 16;60(6):802–807. doi: 10.1002/ijc.2910600613. [DOI] [PubMed] [Google Scholar]
  41. Uberti J. P., Joshi I., Ueda M., Martilotti F., Sensenbrenner L. L., Lum L. G. Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC-restricted cytotoxicity. Clin Immunol Immunopathol. 1994 Mar;70(3):234–240. doi: 10.1006/clin.1994.1034. [DOI] [PubMed] [Google Scholar]
  42. Ubhi S. S., Horsburgh T., Veitch P. S., Bell P. R. Anti-CD3 enhancement of cellular cytotoxicity in cancer patients treated with interleukin-2. Anticancer Res. 1991 Mar-Apr;11(2):931–935. [PubMed] [Google Scholar]
  43. Ullman K. S., Northrop J. P., Verweij C. L., Crabtree G. R. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol. 1990;8:421–452. doi: 10.1146/annurev.iy.08.040190.002225. [DOI] [PubMed] [Google Scholar]
  44. Yoshizawa H., Chang A. E., Shu S. Y. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res. 1992 Mar 1;52(5):1129–1136. [PubMed] [Google Scholar]
  45. de Waal Malefyt R., Yssel H., de Vries J. E. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol. 1993 Jun 1;150(11):4754–4765. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES